Screener
Protagonist Therapeutics PTGX AU — PP&E (Net)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Protagonist Therapeutics’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:28 PM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-019696
Depreciation expense for the years ended December 31, 2025, 2024 and 2023, was $1,225,000, $894,000 and $977,000, respectively. As of December 31, 2025, 2024 and 2023, $40,000, $47,000 and $56,000, respectively, of the Company’s property and equipment, net, was located in Australia. The remainder of the Company’s property and equipment, net was located in the United States.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Protagonist Therapeutics's AU — PP&E (net)?
- Protagonist Therapeutics (PTGX) reported AU — PP&E (net) of $40K in Q4 2025.
- How has Protagonist Therapeutics's AU — PP&E (net) changed year-over-year?
- Protagonist Therapeutics's AU — PP&E (net) decreased by 14.9% year-over-year, from $47K to $40K.
- What does AU — PP&E (net) mean?
- This metric represents the net book value of tangible assets, such as laboratory equipment, facilities, and infrastructure, located within the Australian geographic segment. It reflects the company's investment in physical capital necessary to support research, development, and operational activities in that region. Monitoring this balance helps investors assess the scale of regional infrastructure and the depreciation profile of assets supporting clinical-stage operations.
Ask your AI about Protagonist Therapeutics's au — pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude